LU87007A1 - Compositions pharmaceutiques a base d'urokinase - Google Patents
Compositions pharmaceutiques a base d'urokinase Download PDFInfo
- Publication number
- LU87007A1 LU87007A1 LU87007A LU87007A LU87007A1 LU 87007 A1 LU87007 A1 LU 87007A1 LU 87007 A LU87007 A LU 87007A LU 87007 A LU87007 A LU 87007A LU 87007 A1 LU87007 A1 LU 87007A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- urokinase
- pro
- unit dose
- injection
- dose
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 108010073863 saruplase Proteins 0.000 claims description 97
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 86
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 86
- 229960005356 urokinase Drugs 0.000 claims description 85
- 238000002347 injection Methods 0.000 claims description 36
- 239000007924 injection Substances 0.000 claims description 36
- 238000001802 infusion Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 10
- 229960002897 heparin Drugs 0.000 claims description 10
- 229920000669 heparin Polymers 0.000 claims description 10
- 230000002195 synergetic effect Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000003527 fibrinolytic agent Substances 0.000 claims description 4
- 230000002537 thrombolytic effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229960000103 thrombolytic agent Drugs 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 238000011260 co-administration Methods 0.000 claims description 2
- 230000003389 potentiating effect Effects 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 4
- 238000002586 coronary angiography Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 239000000006 Nitroglycerin Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 201000010516 hypertrophic cardiomyopathy 7 Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868623823A GB8623823D0 (en) | 1986-10-03 | 1986-10-03 | Therapeutic lysis of fibrin blood clots |
| GB8623823 | 1986-10-03 | ||
| GB868628741A GB8628741D0 (en) | 1986-12-02 | 1986-12-02 | Therapeutic lysis of fibrin blood clots |
| GB8628741 | 1986-12-02 | ||
| GB878707551A GB8707551D0 (en) | 1987-03-30 | 1987-03-30 | Therapeutic lysis of fibrin blood clots |
| GB8707551 | 1987-03-30 | ||
| GB8715678 | 1987-07-03 | ||
| GB878715678A GB8715678D0 (en) | 1987-07-03 | 1987-07-03 | Therapeutic lysis of fibrin blood clots |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU87007A1 true LU87007A1 (fr) | 1988-05-03 |
Family
ID=27449820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU87007A LU87007A1 (fr) | 1986-10-03 | 1987-10-01 | Compositions pharmaceutiques a base d'urokinase |
Country Status (19)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8503097A (nl) * | 1985-11-11 | 1987-06-01 | Leuven Res & Dev Vzw | Geneesmiddel met thrombolytische werking. |
-
1987
- 1987-09-18 NL NL8702234A patent/NL8702234A/nl not_active Application Discontinuation
- 1987-09-18 HU HU874172A patent/HUT47032A/hu unknown
- 1987-09-22 DE DE19873731776 patent/DE3731776A1/de not_active Ceased
- 1987-09-28 FR FR8713486A patent/FR2605225B1/fr not_active Expired - Fee Related
- 1987-09-28 BE BE8701102A patent/BE1002058A4/fr active
- 1987-09-28 CH CH3749/87A patent/CH678599A5/de not_active IP Right Cessation
- 1987-10-01 LU LU87007A patent/LU87007A1/fr unknown
- 1987-10-01 PT PT85848A patent/PT85848B/pt unknown
- 1987-10-01 GR GR871528A patent/GR871528B/el unknown
- 1987-10-01 CA CA000548421A patent/CA1323300C/en not_active Expired - Fee Related
- 1987-10-01 IL IL84061A patent/IL84061A0/xx unknown
- 1987-10-01 SE SE8703788A patent/SE466531B/sv not_active IP Right Cessation
- 1987-10-01 FI FI874320A patent/FI874320A7/fi not_active IP Right Cessation
- 1987-10-01 NO NO874143A patent/NO874143L/no unknown
- 1987-10-02 KR KR1019870011020A patent/KR960002738B1/ko not_active Expired - Fee Related
- 1987-10-02 DK DK519287A patent/DK519287A/da not_active Application Discontinuation
- 1987-10-02 IT IT8748444A patent/IT1230114B/it active
- 1987-10-02 AU AU79325/87A patent/AU7932587A/en not_active Abandoned
- 1987-10-08 MY MYPI87002871A patent/MY101943A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE8703788L (sv) | 1988-04-04 |
| FI874320L (fi) | 1988-04-04 |
| CA1323300C (en) | 1993-10-19 |
| FR2605225A1 (fr) | 1988-04-22 |
| PT85848B (en) | 1990-01-12 |
| IT1230114B (it) | 1991-10-07 |
| NL8702234A (nl) | 1988-05-02 |
| DK519287A (da) | 1988-04-04 |
| SE8703788D0 (sv) | 1987-10-01 |
| KR880004821A (ko) | 1988-06-27 |
| GR871528B (en) | 1988-02-23 |
| SE466531B (sv) | 1992-03-02 |
| FI874320A7 (fi) | 1988-04-04 |
| FR2605225B1 (fr) | 1994-02-04 |
| KR960002738B1 (ko) | 1996-02-26 |
| FI874320A0 (fi) | 1987-10-01 |
| NO874143D0 (no) | 1987-10-01 |
| IT8748444A0 (it) | 1987-10-02 |
| HUT47032A (en) | 1989-01-30 |
| IL84061A0 (en) | 1988-03-31 |
| DK519287D0 (da) | 1987-10-02 |
| DE3731776A1 (de) | 1988-05-05 |
| NO874143L (no) | 1988-04-05 |
| BE1002058A4 (fr) | 1990-06-12 |
| CH678599A5 (enrdf_load_stackoverflow) | 1991-10-15 |
| AU7932587A (en) | 1988-04-14 |
| MY101943A (en) | 1992-02-15 |
| PT85848A (en) | 1987-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1001425A4 (fr) | Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association. | |
| US5906988A (en) | Methods of treatment using ranolazine and related piperazine derivatives | |
| FI120182B (fi) | Trombolyyttisesti aktiivisten proteiinien ja antikoagulanttien yhdistelmiä ja niiden käyttöjä | |
| LU86444A1 (fr) | Nouvelle compostion d'activateur tissulaire du plasminogene | |
| JP2820699B2 (ja) | 血栓溶解剤 | |
| JPH03503289A (ja) | 膵臓炎及び膵臓移植組織中の免疫拒絶の治療に於けるｓ‐アデノシル‐メチオニン | |
| Payseur et al. | Pulmonary alveolar proteinosis: a progressive, diffuse, fatal pulmonary disease | |
| Salvati et al. | Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease | |
| JPS6391327A (ja) | 有機化合物に関する改良 | |
| LU87007A1 (fr) | Compositions pharmaceutiques a base d'urokinase | |
| BE1013921A3 (fr) | Composition pharmaceutique pour traiter les maladies degeneratives. | |
| Schoebel et al. | Chronic‐intermittent urokinase therapy in patients with end‐stage coronary artery disease and refractory angina pectoris—A pilot study | |
| EP0106812B1 (en) | Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction | |
| JPH0273022A (ja) | 組織プラスミノーゲン活性化因子を用いた薬学的製剤 | |
| FR2806911A1 (fr) | Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires | |
| Villota et al. | Cocaine-induced coronary thrombosis and acute myocardial infarction | |
| WO1992022202A1 (en) | Thrombolytic and perfluorochemical treatment for myocardial infraction | |
| CN1320922C (zh) | 基于用丙二烯氧合酶将脂质过氧化物酶消除的心脏保护疗法 | |
| GB2197195A (en) | Urokinase compositions for treating thrombosis | |
| JPH089546B2 (ja) | 抗血栓医薬組成物 | |
| Hillis | Prostaglandins and the cardiovascular system | |
| Serebruany et al. | Serial changes of the plasma prostanoids during myocardial ischemia—reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor | |
| FGE | rapid arterial smooth muscle relaxation and increased blood and adenine nucleotides are attenuated when en flow. tional integrity is compromised (5)(Fig. 3). Endotheliti modulation of Vascular endothelium also modulates vascular tone by activat-ing vasoconstrictors, such as angiotensin I, and inactivating | |
| Harker | Thrombosis: its role and prevention in cardiovascular events--Part I. Concepts of thrombogenesis and its prevention | |
| Di Pasquale et al. | Thrombolysis plus heparin versus heparin alone in the acute phases of unstable angina: preliminary findings |